 |
 |
 |
 |
 |
|
 |
 |
 |
 |
  |
Canada
Updated May 2009
Canada has been generally supportive of minimization of highly enriched uranium (HEU) but does not appear to have an articulated and coordinated policy on the issue. While Canada's Atomic Energy of Canada Limited (AECL) has converted or is in the process of converting the nuclear fuel in its research reactors from highly enriched uranium (HEU) to low-enriched uranium (LEU), it continues to employ HEU "targets" for the production of medical isotopes in its National Research Universal (NRU) reactor at Chalk River Laboratories in Ontario. [For more information on the production of medical isotopes, see the "HEU Use for Radioisotope Production" section in Civilian Uses of HEU.]
|
Overview of Canadian HEU Holdings
Canada is a non-nuclear weapons state signatory to the Nuclear Non-Proliferation Treaty (NPT), and thus its entire declared stockpile of highly enriched uranium is civilian-use and its facilities are all subject to IAEA safeguards. There are, however, no public Canadian declarations of HEU holdings. Unlike several other states, Canada does not provide this information to the International Atomic Energy Agency (IAEA) as part of an annual declaration of plutonium stocks (INFCIRC/549).[1]
Canada has HEU in the form of nuclear fuel, HEU targets for the production of medical isotopes, as well as HEU scraps from target fabrication. It has converted or plans to convert or decommission all of its research reactors to use LEU fuel.[2] As of February 2006, three reactors continued to have HEU in their cores.[3] Medical isotope production at the NRU reactor involves the irradiation of 93% enriched uranium targets; after this short irradiation period, they are typically still at a 90% enrichment level. Discharged targets are stored in a fissile solution storage tank or as concretized waste.
Canada does not have domestic enrichment capabilities at present, nor are there current plans to create a capability to produce HEU. It uses HEU imported from the United States (exports licensed by the U.S. Nuclear Regulatory Commission). According to one estimate, of 2,169 kilograms (kg) of HEU sent from the United States to Canada through 1992, approximately 1,184 had been repatriated to the United States, while an additional 16 kg were returned and 20 kg sent by 1996. There are an estimated 1,229 kg of U.S.-origin HEU in Canada (2,169–1,184–16+20).[4]
Conversion and Shutdown of HEU-Fueled Reactors and Reactor Projects
Canada is in the process of converting its Slowpoke (Safe Low-Power Kritical Experiment) reactors in Alberta, Saskatchewan, and Halifax to LEU fuels.[5] It has already converted the MNR pool reactor at McMaster University, Slowpoke reactor in Montreal, and the NRU reactor at Chalk River to LEU fuel.
Canada has shut down its NRX heavy water reactor (in 1993), and the Slowpoke reactors PTR (1990), at Kanata (1989), Ottawa (1984), and Toronto (1998), all of which employed HEU fuel. (For information on efforts to convert radioisotope production, see the "Conversion of Radioisotope Production" section, below.)
Radioisotope Production
Canada is the world's leading producer of the radioisotope molybdenum-99 (Mo-99), which has a 2.7-day half-life and decays to 6-hour half-life technetium-99m, a gamma ray emitter widely used in cancer, heart disease and brain disorder treatment.[6] It is the main source of supply of medical isotopes to the United States.
Click to enlarge |
There are, however, concerns associated with the degree to which patients worldwide rely upon a 50-year old reactor, the NRU, for the production of Mo-99. In addition, in May 2008, construction of the reactors (Multipurpose Applied Physics Lattice Experiment or MAPLE) intended to replace the NRU was cancelled.
National Research Universal (NRU) Reactor
Mo-99 has been produced since the late 1950s in the AECL's NRU reactor at Chalk River, using uranium targets fabricated from HEU supplied by the United States. NRU also operated on HEU fuel but converted to LEU fuel in 1991-92. In August 2006, Canada's nuclear regulator, the Canadian Nuclear Safety Commission (CNSC), extended the NRU's operating license until 2011, provided certain safety upgrades were completed.
Interruptions in the supply of Canadian Tc-99m have periodically led to calls for additional production facilities.[7] Most recently, a scheduled maintenance shutdown in November 2007 was extended when CNSC officials discovered that not all of the safety upgrades mandated in 2006 had been completed, and thus the reactor had been in violation of its operating license.[8] CNSC prohibited NRU from restarting operation until the connection of two heavy water pumps to an emergency power supply, was completed.The delay in start-up and the resulting shortfall in isotope production triggered a political firestorm. The head of the CNSC, who would not authorize the restart without completion of the upgrades, was demoted and the NRU was given permission to start up without the safety upgrade by emergency legislation (Bill C-38) passed by Canada's House of Commons. (It should be noted that the issue of HEU use did not prominently figure in the discussion by the House of Commons; at the time, the MAPLE reactor project was still ongoing—the MAPLEs were expected to employ HEU targets like NRU.)
The NRU was restarted for isotope production on December 16. The CNSC resumed full regulatory oversight of the reactor only after the safety upgrades were completed in April 2008.[9] The current NRU license will expire in 2011.
Multipurpose Applied Physics Lattice Experiment (MAPLE) Reactors
|
In the mid-1990s, Canada developed a plan to replace NRU with a new reactor type, designated MAPLE. Eventually, two new reactors, MAPLE 1 and 2, were planned, along with a New Processing Facility (NPF). Originally, the MAPLEs were supposed to go online in 1999 and 2000. However, the project faced multiple delays due to technical problems, and failed to obtain an operating license.
In May 2008, AECL made the decision to halt construction of the reactors due to "costs of further development, as well as the time frame and risks involved."[10] In addition, concerns about "continued commercial viability" of medical isotopes from HEU reportedly also figured in AECL's decision to scrap the MAPLEs.[11] MDS Nordion, the Canadian isotope supplier, was "not consulted" by the AECL on the decision, though AECL committed to work with the company to ensure isotope supply after 2011, when NRU's operating license is set to expire.[12] In July, Nordion filed a lawsuit against AECL, stating that it was "disappointed that AECL and the Government decided to abandon the MAPLE project without establishing a clear plan for the long-term [radioisotope] supply."[13]
The U.S. exported 45 kg of HEU for use in the MAPLEs.[14] However, since the reactors have been cancelled, a decision will have to be made on the use of this material. No official statements have been made to date on whether or not it will be returned to the United States.[15]
Conversion of Radioisotope Production
Pursuant to then-U.S. law regarding the export of HEU (for more information, see "U.S. 1992 Schumer Amendment" section in Past and Current Efforts to Reduce Civilian HEU), Canadian isotope producer MDS Nordion agreed in the late 1990s to undertake a development program to convert from HEU to LEU targets in order to remain eligible for HEU exports from the United States. According to scientists involved in the RERTR program at Argonne National Laboratory (for more information on RERTR, see "U.S. RERTR Program" section in Past and Current Efforts to Reduce Civilian HEU), Nordion was particularly cooperative with the program each time it was applying for a new license to import U.S. HEU.[16]
In 2003, however, Nordion concluded that conversion was not feasible without a significant interruption in production and that the new processing facility, which had already been constructed, could not handle LEU targets (despite initial plans to build a facility that could be converted to handle LEU). Thus, construction of a new processing facility would be required, entailing unacceptable costs in the view of the Canadian producer ($90 million Canadian). This led the company to further curtail cooperation with the RERTR program, focusing instead on seeking relief from the law imposing restrictions on U.S. transfers of HEU and ensuring continued exports to Canada.
An amendment to this end was promoted by Senator Burr and passed as part of the Energy Bill signed into law in August 2005.[17] Under the new law, U.S. HEU may be exported to medical isotope producers in Europe and Canada (though not elsewhere) without the condition of agreeing to convert to LEU. The law also required a National Academy of Sciences (NAS) study into the feasibility of producing Mo-99 using LEU, however. Nordion has participated in this study, and contends that conversion is possible, though it would take seven to ten years and would be quite costly.[18] In April 2009, Nordion announced that it would partner with Canada's national laboratory for particle and nuclear physics, TRIUMF, to conduct a joint feasibility study on "producing a viable and reliable supply" of photo-fission produced Mo-99. "Medical isotopes produced using photo fission employ the use of a linear accelerator rather than a nuclear reactor; as such, the need to ship and handle highly enriched uranium is eliminated in favour of naturally occurring uranium," a Nordion release stated.
Policy Issues
Canada is a leading advocate of nonproliferation. It played a leading role in promoting the indefinite extension of the NPT in 1995; is a strong proponent of the CTBT and of a (verifiable) FMCT; was a founding member of the Nuclear Suppliers Group and a strong advocate of significant export controls; hosted and promotes the G8 Kananaskis meeting that established the agenda for the G8 global partnership against the spread of weapons and materials of mass destruction; supports the PSI initiative as an important response to the challenges posed by proliferation; and is a proponent of UNSC Resolution 1540.(For more information on Canada's membership in international organizations and treaty commitments, see NTI's Inventory)
Canada has also been a partner nation in the Global Initiative to Combat Nuclear Terrorism since its establishment in 2006. In a joint statement issued by the Initiative chairs after its third annual meeting in Astana, Kazakhstan in 2007, the key Initiative priorities included "minimizing the use of highly enriched uranium and plutonium in civilian facilities and activities." However, the Global Initiative has yet to develop plans or agreements to make this commitment concrete. For its part, Canada has yet to commit to a position on pursuing efforts to end Canada's use of HEU for radioisotope production, though it did commit to ending the use of HEU in reactor fuel when it concluded the North American Security and Prosperity Partnership in 2005. The lack of a strong government position, together with Nordion lobbying in the United States to amend U.S. legislation covering HEU exports, has led to a weakening of the position of proponents of HEU minimization. Until Canada lends stronger support to HEU minimization and initiates work to end the use of HEU in the production of medical isotopes, it will remain difficult to consolidate a global norm against HEU minimization.
Sources:
[1] The nine countries that report their holdings to the IAEA annually as part of INFCIRC/549 are major holders of separated plutonium.
[2] As of June 2008, Dalhousie University (Halifax) planned to decommission its Slowpoke reactor. "University Environmental Health and Safety Committee Report to DPMG: June 2008," http://professionalandmanagerialgroup.dal.ca/Files/2008_Health_and_Safety.pdf.
[3] CNS Interview RERTR program official, in Vienna, Austria, February 9, 2006.
[4] Estimated by Frank von Hippel based on data in NRC reports.
[5] CNS Interview RERTR program official, in Vienna, Austria, February 9, 2006.
[6] For additional information on isotope production, see Cristina Hansell, "Nuclear Medicine's Double Hazard: Imperiled Treatment and the Risk of Terrorism," Nonproliferation Review, July 2008, 15/2, pp. 185-208.
[7] For example, risks or reliance on a single isotope were highlighted by a 1991 strike at a Canadian plant that processed Mo-99.
[8] Canadian Nuclear Safety Commission (CNSC), "NRU Reactor Events," August 1, 2008, http://www.nuclearsafety.gc.ca/eng/mediacentre/issues/nruevents/index.cfm.
[9] CNSC, "CNSC resumes full regulatory oversight of NRU reactor," April 10, 2008, http://www.nuclearsafety.gc.ca/eng/mediacentre/releases/news_release.cfm?news_release_id=306.
[10] Atomic Energy of Canada Limited, "AECL to Discontinue Development of the MAPLE Reactors," May 16, 2008, http://www.aecl.ca/NewsRoom/News/Press-2008/080516.htm.
[11] Daniel Horner, "Questions about future of HEU had role in Maple's end," Inside NRC, May 26, 2008, pp. 4-5.
[12] MDS Nordion, "MDS Responds to AECL and Government of Canada Announcements Regarding Maple Project," May 16, 2008, http://www.mds.nordion.com/documents/news-releases/2008/MDS_Response_to_AECL_Government.pdf.
[13] MSD Nordion, "MDS Commences Arbitration against AECL over Cancelled MAPLE Project and
Files $1.6 Billion Court Claim against AECL and the Government of Canada," July 9, 2008, http://www.mds.nordion.com/documents/news-releases/2008/AECL_Arbitration_FINAL.pdf.
[14] Daniel Horner, "Questions about future of HEU had role in Maple's end," Inside NRC, May 26, 2008, pp. 4-5. In addition, the U.S. NNSA contractually committed in 2004 to supply Canada's AECL with 1,500 kg of uranium enriched to 19.75 percent (i.e. LEU) for use as fuel in reactors at Chalk River Laboratories (NRU and MAPLEs). As of August 2008, approximately 1,136 kg have been supplied, 224 kg of which were U-235. The shipments are expected to be completed by the end of 2008. See "Y-12 close to fulfilling isotopes contract," Nuclear Weapons and Materials Monitor, August 4, 2008, pg. 12.
[15] For a discussion of the status of the HEU targets for the MAPLEs, please see Ian MacLeod, "How to solve a problem like 45kg of bomb-grade uranium?" Ottawa Citizen, September 5, 2008,
http://www.canada.com/ottawacitizen/news/story.html?id=f89220ee-ebff-49cb-8660-f5d179bd7402.
[16] For more details on Nordion's cooperation with RERTR, see: George Vandegrift, ‘‘ANL (GFV) Perspective on Conversion of Mo-99 Production from High- to Low-Enriched Uranium," presentation for the National Academy of Sciences study on the production of medical isotopes without HEU, mandated by Section 630 of the Energy Policy Act of 2005, Argonne National Laboratory, dels.nas.edu/nrsb/presentations/vandergrift.pdf.
[17] For details about Nordion lobbying and the Burr Amendment, see Alan Kuperman, "Bomb-Grade
Bazaar," Bulletin of the Atomic Scientists, March/April 2006, pp. 44-50.
[18] For information on recent discussions about converting Mo-99 production, see Ann MacLachlan, "NRG to Study Potential for Use of LEU for Mo-99," NuclearFuel, December 17, 2007, p. 1, and "Nuclear Medicine's Double Hazard."
This material is
produced independently for NTI by the Center for Nonproliferation Studies at the Monterey Institute of International Studies and does not
necessarily reflect the opinions of and has not been independently verified by NTI or its directors, officers, employees, agents.
Copyright © 2008 by MIIS.
